The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 1
Abstract
Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised. In the meantime, hepatitis C patients with sustained virologic response (SVR) achieved with previous treatments have been forgotten. Hepatitis C patients with SVR achived by pegylated interferon + ribavirin (INF + RIB) treatment are followed and it is investigated whether cirrhosis, hepatocellular carcinoma (HCC) and/or decompensation developed or not in these patients. Materials and Methods: One hundred thirty-five patients with hepatitis C virus who achieved SVR with pegylated INF alpha + RIB treatment between 2006 and 2010 are included in the study. At least twice a year, these patients were followed-up with ultrasonography, alpha fetoprotein and routine laboratory tests. Results: Out of the patients, 97.8% were genotype 1 and 95% were evaluated with biopsy before the treatment. One hundred twenty non-cirrhotic patients and 15 patients with compensated cirrhosis were followed for a period of 10.6 years (distribution: 9-13 years). None of the non-cirrhotic patients developed cirrhosis or HCC. HCC was developed in one of 15 cirrhotic patients (6 years after the treatment), resulting in the death of the patient. There were no decompensation case. Conclusion: It is evaluated that non-cirrhotic hepatitis C patients who achieved SVR with pegylated INF can be followed in a wider range of time. There should be a strict follow-up of cirrhotic patients, especially for HCC development.
Authors and Affiliations
Osman Özdoğan, Serkan Yaraş
Keywords
Related Articles
- EP ID EP684576
- DOI 10.4274/vhd.galenos.2019.2019.0042
- Views 147
- Downloads 0
The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Material...
Relationship Between Basic Laboratory Results and Fibrosis in Chronic Hepatitis B Patients
Objectives: Liver biopsy (LB) is an important cornerstone in decision to start treatment for chronic hepatitis B (HB). Viral load and liver function tests are performed to determine the most appropriate time. In this stu...
The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin
Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised. In the meantime, hepatitis C patients with sustained virologic response (SVR) achieved with previous treatments hav...
How Aware are We of the Immune Status of Hepatitis B and Hepatitis A in Chronic Hepatitis C Patients? A Multicenter Retrospective Study from Turkey
Objectives: Patients with chronic hepatitis C virus (HCV) infection and superinfection by hepatitis A or hepatitis B virus have higher morbidity and mortality when compared with those without HCV infection. The aim of th...
The Evaluation of a Hundred Eleven Adult Patients with Acute Hepatitis
Objectives: We aimed to evaluate the etiological, epidemiological and laboratory characteristics of adult patients admitted to our hospital with acute hepatitis. Materials and Methods: The patients with alanine aminotra...